ArticleFoods (Basel, Switzerland)2026
Optimization and Validation of an HPLC-PDA Method for the Determination of (6S)-5-Methyltetrahydrofolate in Diverse Dietary Supplement Formulations.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Analytical methods for (6S)-5-methyltetrahydrofolate (5-MTHF) have mainly been reported for specific formulation types, such as tablets, chewable tablets, powders, and liquid formulations, despite its increasing use in dietary supplement and health functional food formulations with diverse matrix compositions. In this study, high-performance liquid chromatography with photodiode array detection analytical conditions and sample preparation approaches were systematically compared and optimized to improve applicability across different formulation matrices. Chromatographic performance was evaluated under standard solution conditions, followed by a comparative assessment of sample preparation conditions in tablet, chewable tablet, powder, and liquid formulations. An ultrasonic pretreatment approach without thermal treatment provided consistent recovery and repeatability across all the tested formulations. The optimized analytical conditions showed linear detector response (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.